Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Titel:
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Auteur:
Jhaveri, K. Eli, L.D. Wildiers, H. Hurvitz, S.A. Guerrero-Zotano, A. Unni, N. Brufsky, A. Park, H. Waisman, J. Yang, E.S. Spanggaard, I. Reid, S. Burkard, M.E. Vinayak, S. Prat, A. Arnedos, M. Bidard, F.-C. Loi, S. Crown, J. Bhave, M. Piha-Paul, S.A. Suga, J.M. Chia, S. Saura, C. Garcia-Saenz, J.Á. Gambardella, V. de Miguel, M.J. Gal-Yam, E.N. Raphael, A. Stemmer, S.M. Ma, C. Hanker, A.B. Ye, D. Goldman, J.W. Bose, R. Peterson, L. Bell, J.S.K. Frazier, A. DiPrimeo, D. Wong, A. Arteaga, C.L. Solit, D.B.